Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Dianthus Therapeutics Inc (NASDAQ: DNTH) was $35.84 for the day, down -3.63% from the previous closing price of $37.19. In other words, the price has decreased by -$3.63 from its previous closing price. On the day, 0.52 million shares were traded. DNTH stock price reached its highest trading level at $37.78 during the session, while it also had its lowest trading level at $35.56.
Ratios:
Our analysis of DNTH’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 13.12 and its Current Ratio is at 13.12. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 03, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $48.Oppenheimer initiated its Outperform rating on October 03, 2024, with a $48 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 09 ’25 when Savitz Ryan sold 20,000 shares for $35.00 per share. The transaction valued at 700,000 led to the insider holds 0 shares of the business.
RYAN SAVITZ bought 20,000 shares of DNTH for $636,000 on Sep 09 ’25.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNTH now has a Market Capitalization of 1427013504 and an Enterprise Value of 897571264. For the stock, the TTM Price-to-Sale (P/S) ratio is 294.23 while its Price-to-Book (P/B) ratio in mrq is 3.80. Its current Enterprise Value per Revenue stands at 184.914 whereas that against EBITDA is -6.914.
Stock Price History:
The Beta on a monthly basis for DNTH is 1.53, which has changed by 0.3157122 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, DNTH has reached a high of $39.87, while it has fallen to a 52-week low of $13.36. The 50-Day Moving Average of the stock is 37.04%, while the 200-Day Moving Average is calculated to be 62.73%.
Shares Statistics:
DNTH traded an average of 593.58K shares per day over the past three months and 729910 shares per day over the past ten days. A total of 32.18M shares are outstanding, with a floating share count of 29.04M. Insiders hold about 27.05% of the company’s shares, while institutions hold 86.26% stake in the company. Shares short for DNTH as of 1757894400 were 5123594 with a Short Ratio of 8.63, compared to 1755216000 on 5983909. Therefore, it implies a Short% of Shares Outstanding of 5123594 and a Short% of Float of 15.100000999999999.
Earnings Estimates
The performance of Dianthus Therapeutics Inc (DNTH) in the stock market is under the watchful eye of 6 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.87, with high estimates of -$0.75 and low estimates of -$1.09.
Analysts are recommending an EPS of between -$3.3 and -$3.83 for the fiscal current year, implying an average EPS of -$3.5. EPS for the following year is -$3.63, with 5.0 analysts recommending between -$3.05 and -$4.47.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for DNTH’s current fiscal year. The highest revenue estimate was $5.03M, while the lowest revenue estimate was $1.36M, resulting in an average revenue estimate of $2.52M. In the same quarter a year ago, actual revenue was $6.24M
